These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 8351515)

  • 81. Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells.
    Politz JC; Taneja KL; Singer RH
    Nucleic Acids Res; 1995 Dec; 23(24):4946-53. PubMed ID: 8559650
    [TBL] [Abstract][Full Text] [Related]  

  • 82. In vitro and in vivo anti-influenza A virus activity of antisense oligonucleotides.
    Abe T; Mizuta T; Suzuki S; Hatta T; Takai K; Yokota T; Takaku H
    Nucleosides Nucleotides; 1999; 18(6-7):1685-8. PubMed ID: 10474246
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A novel drug screening assay for papillomavirus specific antiviral activity.
    Clark PR; Roberts ML; Cowsert LM
    Antiviral Res; 1998 Feb; 37(2):97-106. PubMed ID: 9588842
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A.
    Mizuta T; Fujiwara M; Hatta T; Abe T; Miyano-Kurosaki N; Shigeta S; Yokota T; Takaku H
    Nat Biotechnol; 1999 Jun; 17(6):583-7. PubMed ID: 10385324
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.
    Lee DS; Jung KE; Yoon CH; Lim H; Bae YS
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4110-20. PubMed ID: 16189087
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A
    Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
    [No Abstract]   [Full Text] [Related]  

  • 87. Comparative evaluation of seven oligonucleotide analogues as potential antisense agents.
    Morvan F; Porumb H; Degols G; Lefebvre I; Pompon A; Sproat BS; Rayner B; Malvy C; Lebleu B; Imbach JL
    J Med Chem; 1993 Jan; 36(2):280-7. PubMed ID: 8423598
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression?
    Stein CA; Tonkinson JL; Yakubov L
    Pharmacol Ther; 1991 Dec; 52(3):365-84. PubMed ID: 1668180
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.
    Goodchild J; Agrawal S; Civeira MP; Sarin PS; Sun D; Zamecnik PC
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5507-11. PubMed ID: 3041414
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
    Rubenstein M; Guinan P
    In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Genetic therapy for transplant vascular sclerosis.
    Bennett CF; Stepkowski SM
    Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
    [No Abstract]   [Full Text] [Related]  

  • 93. Hydrophobized antiviral antibodies and antisense oligonucleotides.
    Severin ES; Melik-Nubarov NS; Ovcharenko AV; Vinogradov SV; Kiselev VI; Kabanov AV
    Adv Enzyme Regul; 1991; 31():417-30. PubMed ID: 1877397
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Oligodeoxynucleotides as antisense inhibitors of gene expression.
    Ghosh MK; Cohen JS
    Prog Nucleic Acid Res Mol Biol; 1992; 42():79-126. PubMed ID: 1574591
    [No Abstract]   [Full Text] [Related]  

  • 95. Transient inhibition of foot-and-mouth disease virus infection of BHK-21 cells by antisense oligonucleotides directed against the second functional initiator AUG.
    Gutiérrez A; Rodríguez A; Pintado B; Sobrino F
    Antiviral Res; 1993 Sep; 22(1):1-13. PubMed ID: 8250540
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antisense strategies: functions and applications in immunology.
    Varga LV; Tóth S; Novák I; Falus A
    Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Antisense oligodeoxynucleotides as antiviral agents.
    Cohen JS
    Antiviral Res; 1991 Sep; 16(2):121-33. PubMed ID: 1799276
    [No Abstract]   [Full Text] [Related]  

  • 98. Water-soluble block polycations as carriers for oligonucleotide delivery.
    Kabanov AV; Vinogradov SV; Suzdaltseva YG; Alakhov VYu
    Bioconjug Chem; 1995; 6(6):639-43. PubMed ID: 8608176
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Perspectives in antisense therapeutics.
    Agrawal S; Iyer RP
    Pharmacol Ther; 1997; 76(1-3):151-60. PubMed ID: 9535177
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The binding of anti-DNA antibodies to phosphorothioate oligonucleotides in a solid phase immunoassay.
    Pisetsky DS; Reich CF
    Mol Immunol; 1998 Dec; 35(18):1161-70. PubMed ID: 10199390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.